Graham Capital Management L.P. Invests $4.25 Million in Ralliant Corporation $RAL

Graham Capital Management L.P. acquired a new position in Ralliant Corporation (NYSE:RAL) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 83,512 shares of the company’s stock, valued at approximately $4,252,000.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Ralliant by 10.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after purchasing an additional 1,415,327 shares during the last quarter. Dodge & Cox grew its stake in shares of Ralliant by 13.3% in the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after purchasing an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new position in shares of Ralliant in the 2nd quarter worth approximately $257,200,000. State Street Corp acquired a new position in shares of Ralliant in the 2nd quarter worth approximately $213,096,000. Finally, Invesco Ltd. grew its stake in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after purchasing an additional 1,835,128 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. TD Cowen lifted their price objective on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 20th. Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Wednesday, May 27th. Oppenheimer lifted their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Finally, Truist Financial reissued a “buy” rating and issued a $68.00 target price (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $67.30.

Ralliant Stock Performance

Ralliant stock opened at $68.76 on Wednesday. The firm’s 50 day simple moving average is $54.11 and its 200-day simple moving average is $50.13. The company has a market cap of $7.70 billion and a P/E ratio of -6.28. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $69.93.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities research analysts predict that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is presently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.